Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06294431
Other study ID # RADX-P-2406
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 22, 2024
Est. completion date October 2024

Study information

Verified date May 2024
Source Radicle Science
Contact Study Manager
Phone 760-281-3898
Email studymgmt@radiclescience.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on cognitive function and related health outcomes


Description:

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) endorse a desire for better concentration, (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded. Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic, there are no in-person visits or assessments for this real-world evidence study.


Recruitment information / eligibility

Status Recruiting
Enrollment 1901
Est. completion date October 2024
Est. primary completion date July 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 105 Years
Eligibility Inclusion Criteria: - Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed - Resides in the United States - Endorses better concentration or cognitive function (fewer feelings of brain fog) as a primary desire - Has the opportunity for at least 20% improvement in their primary health outcome - Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study Exclusion Criteria: - Report being pregnant, trying to become pregnant, or breastfeeding - Unable to provide a valid US shipping address and mobile phone number - Reports current enrollment in another clinical trial - Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) - Unable to read and understand English - Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety lak - Reports a diagnosis or cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure - Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products - Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) - Lack of reliable daily access to the internet

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo Control Form 1
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
Clarity Active Study Product 1.1 Usage
Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
Placebo Control Form 2
Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
Clarity Active Study Product 2.1 Usage
Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
Placebo Control Form 3
Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
Clarity Active Study Product 3.1 Usage
Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
Clarity Active Study Product 3.2 Usage
Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.

Locations

Country Name City State
United States Radicle Science, Inc Del Mar California

Sponsors (1)

Lead Sponsor Collaborator
Radicle Science

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in mood (emotional distress-depression) Mean difference in mood score as assessed by PROMIS Depression 4A (scale 4-20; where higher scores correspond to more severe depression) 6 weeks
Other Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool Mean difference in specimen assays as surrogates and/or markers for health outcomes. (Optional; among consented participants only) Potentially include saliva (IgG, cytokines, DHEA-S, Estradiol, Progesterone, Testosterone, Cortisol, Melatonin, CRP) blood (1 drop) (Cortisol, Homocysteine, Ferritin, TSH, HbA1c, Insulin, Vitamin D, DHEA-S, Testosterone, Estradiol, FSH, Total Cholesterol, HDL, LDL, Triglycerides, ApoA1, ApoB). Stool (microbial diversity). 6 weeks
Primary Change in cognitive function Mean difference in cognition function score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function) 6 weeks
Secondary Change in fatigue Mean difference in fatigue score as assessed by PROMIS Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue) 6 weeks
Secondary Change in sleep-related impairment Mean difference in sleep-related impairment score as assessed by PROMIS Sleep-Related Impairment 4A (scale 4-20; with higher scores corresponding to greater sleep-related impairment) 6 weeks
Secondary Minimal clinical importance difference (MCID) in cognitive function Likelihood of achieving a MCID in cognitive function, as measured by PROMIS Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function) 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT03708692 - Menstrual Cycle Phases on Recovery and Cognitive Function
Active, not recruiting NCT04505345 - Virtual Reality Cognitive Training in Alcohol Use Disorder N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT02915913 - Effects of Exercise Training on Cognitive Function and Neurotrophic Factors in Overweight Adults N/A
Completed NCT01410097 - Physical and Cognitive Function - Look AHEAD Ancillary Study N/A
Completed NCT03826121 - Efficacy and Safety of Sesame Oil Cake Extract on Improvement of Cognitive Function N/A
Recruiting NCT05621278 - Children to Adults Mental and Psychosomatic Health Study (CAMPS)
Completed NCT05498415 - Feasibility, Acceptability, and Efficacy of the Sleep Move Stand Study N/A
Completed NCT03208569 - Anticholinergic Burden - Treatment Optimization
Completed NCT03793777 - The Effect of Aronia Melanocarpa Extract on Cognitive Function N/A
Recruiting NCT05525299 - Reminiscence-Based Life Review on Copying With Existential Suffering Among Older Cancer Survivors N/A
Completed NCT03698123 - Performance Nutrition for Residents and Fellows N/A
Completed NCT04543500 - Self-regulation of Prefrontal Cortex During Emotional Cognitive Control N/A
Recruiting NCT05891977 - Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults N/A
Recruiting NCT05591885 - Nutrilite Memory Builder on the Improvement of Cognitive Function N/A
Active, not recruiting NCT05575752 - Acute Health Effects of High Temperature Exposure N/A
Completed NCT03716609 - Effects of Magnesium Supplementation on Hemodynamic Parameters and Cognitive Function N/A
Completed NCT02763514 - The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood N/A
Completed NCT02675621 - Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults N/A

External Links